Skip to main content
    A

    Actinium Pharmaceuticals Inc (ATNM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.05
    +0.08 (+7.74%)

    Market Cap: $30.64M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +21.52%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.26
    Range$-0.27 - $-0.24
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.23-8.5%
    60d ago$-0.24-6.3%
    30d ago$-0.24-6.3%
    7d ago$-0.24-6.3%
    Current$-0.26
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.81
    Range$0.80 - $0.83
    2 analysts
    Revenue Consensus
    $18M
    Range$0 - $35M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.81---
    Sep 26EST
    		-$-0.26---
    Jun 26
    Reported Aug 7
    		$0.89$-0.20+545.00%Beat+504.5%
    Mar 26
    Reported May 8
    		$-0.18$-0.22+18.18%Beat+64.7%
    Dec 25
    Reported Mar 30
    		$-0.19$-0.18-5.78%Miss+9.3%
    Sep 25
    Reported Nov 14
    		$-0.16$-0.32+50.00%Beat+56.8%
    Jun 25
    Reported Aug 8
    		$-0.22$-0.35+37.14%Beat+42.1%
    Mar 25
    Reported May 9
    		$-0.51$-0.28-82.14%Miss-64.5%
    Dec 24
    Reported Mar 31
    		$-0.21$-0.39+46.15%Beat+36.4%
    Sep 24
    Reported Nov 14
    		$-0.37$-0.37+0.00%Beat+24.5%
    Jun 24
    Reported Aug 5
    		$-0.38$-0.40+5.00%Beat+34.5%
    Mar 24
    Reported Apr 26
    		$-0.31$-0.52+40.38%Beat+27.9%
    Dec 23
    Reported Mar 29
    		$-0.33$-0.54+38.89%Beat+23.3%
    Sep 23
    Reported Nov 2
    		$-0.49$-0.57+14.04%Beat-28.9%
    Jun 23
    Reported Aug 14
    		$-0.58$-0.49-18.37%Miss-75.8%
    Mar 23
    Reported Apr 3
    		$-0.43$-0.43+0.00%Beat-87.0%
    Dec 22
    Reported Mar 31
    		$-0.43$-0.35-22.86%Miss-19.4%
    Sep 22
    Reported Nov 14
    		$-0.38$-0.31-22.58%Miss-26.7%
    Jun 22
    Reported Aug 12
    		$-0.33$-0.23-43.48%Miss-32.0%
    Mar 22
    Reported May 13
    		$-0.23$-0.31+25.81%Beat+20.7%
    Dec 21
    Reported Mar 25
    		$-0.36$-0.30-20.00%Miss+2.7%
    Sep 21
    Reported Nov 12
    		$-0.30$-0.28-7.14%Miss+16.7%
    Jun 21
    Reported Jul 30
    		$-0.25$-0.29+13.79%Beat+39.0%
    Mar 21
    Reported May 14
    		$-0.29$-0.34+14.71%Beat+67.8%
    Dec 20
    Reported Mar 31
    		$-0.37$-0.37+0.00%Beat+58.9%
    Sep 20
    Reported Oct 23
    		$-0.36$-0.46+21.74%Beat+70.0%
    Jun 20
    Reported Aug 14
    		$-0.41$-0.40-2.50%Miss+54.4%
    Mar 20
    Reported May 8
    		$-0.90$-1.20+25.00%Beat+40.0%
    Dec 19
    Reported Mar 13
    		$-0.90$-1.20+25.00%Beat+40.0%
    Sep 19
    Reported Nov 12
    		$-1.20$-1.20+0.00%Beat+33.3%
    Jun 19
    Reported Aug 9
    		$-0.90$-1.50+40.00%Beat+25.0%
    Mar 19
    Reported May 10
    		$-1.50$-1.70+11.76%Beat+28.6%
    Dec 18
    Reported Mar 19
    		$-1.50$-1.80+16.67%Beat+16.7%
    Sep 18
    Reported Nov 9
    		$-1.80$-1.35-33.33%Miss+33.3%
    Jun 18
    Reported Aug 9
    		$-1.20$-1.90+36.84%Beat+66.7%
    Mar 18
    Reported May 10
    		$-2.10$-2.70+22.22%Beat+50.0%
    Dec 17
    Reported Mar 16
    		$-1.80$-2.62+31.30%Beat+50.0%
    Sep 17
    Reported Nov 3
    		$-2.70$-2.70+0.00%Beat-
    Jun 17
    Reported Aug 4
    		$-3.60$-4.05+11.11%Beat-
    Mar 17
    Reported May 15
    		$-4.20$-3.90-7.69%Miss-
    Dec 16
    Reported Mar 16
    		$-3.60$-4.20+14.29%Beat-

    Key Metrics

    Valuation
    P/E Ratio2.92EV/EBITDA-0.35x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin32.20%Operating Margin78.80%
    ROE45.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.08xQuick Ratio4.08x
    Trading Statistics
    Beta0.27Avg Volume106.71K
    52-Week High$1.7452-Week Low$0.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.08
    SMA 20$1.13
    SMA 50$1.09
    SMA 200$1.12
    EMA 10$1.07
    EMA 20$1.10
    EMA 50$1.09
    EMA 200$1.14

    MACD

    Line: -0.03Signal: -0.00Hist: -0.02

    ADX

    ADX: 20.4+DI: 18.7-DI: 25.5

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$1.13

    Bollinger Bands

    Upper Band$1.27
    Lower Band$0.99
    %B Position2507%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    44.5

    Momentum Oscillators

    Stoch %K14.7
    Stoch %D13.8
    Williams %R-65.5
    ROC (10d)-8.7%
    Momentum-0.10
    CCI (20d)-123.1
    MFI (14d)26.7

    Volatility Measures

    ATR (14d)$0.07(7.1%)
    StdDev (20d)0.07
    Hist Vol55.3%(High)

    Volume Flow

    VWAP$1.02
    OBV-7.6M
    AD Line-8.5M
    CMF (20d)-0.062

    Volume Metrics

    Avg Vol (20d)111.5K
    Vol Ratio1.3x
    VWMA (20d)$1.12

    Pivot Points

    R3$1.08
    R2$1.05
    R1$1.01
    Pivot Point$0.98
    S1$0.94
    S2$0.91
    S3$0.87

    Advanced Oscillators

    TSI-10.02
    Ultimate Osc45.8
    KST-38.88

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$35.00M$0$0$90,000$0$0$810,000$0$0$0$81,000$0
    Cost of Revenue$0$0$-615,000$0$0$0$204,000$0$0$0$199,000$0
    Gross Profit$35.00M$0$615,000$90,000$0$0$-204,000$0$0$0$81,000$0
    Operating Expenses$7.43M$5.90M$6.41M$5.78M$7.50M$16.64M$7.50M$12.60M$12.42M$9.60M$10.42M$14.35M
    R&D$5.38M$4.20M$4.30M$4.25M$4.88M$7.70M$4.81M$9.77M$8.82M$6.63M$8.12M$11.62M
    SG&A$2.06M$1.70M$2.12M$1.53M$2.62M$8.94M$2.69M$2.83M$3.59M$2.96M$2.31M$2.73M
    Operating Income$27.57M$-5,903,000$-6,414,000$-5,692,000$-7,503,000$-16,638,000$-7,505,000$-12,601,000$-12,418,000$-9,597,000$-10,343,000$-14,351,000
    Interest Income$336,000$381,000$474,000$561,000$625,000$700,000$853,000$1.03M$1.06M$927,000$0$1.07M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$27.90M$-5,522,000$-5,940,000$-5,131,000$-6,878,000$-15,938,000$-6,652,000$-11,568,000$-11,353,000$-8,670,000$-9,324,000$-13,276,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$27.90M$-5,522,000$-5,940,000$-5,131,000$-6,878,000$-15,938,000$-6,652,000$-11,568,000$-11,353,000$-8,670,000$-9,324,000$-13,276,000
    EBITDA$28.00M$-5,683,000$-6,856,000$-5,486,000$-7,141,000$-16,433,000$-7,915,000$-12,399,000$-12,229,000$-9,381,000$-10,727,000$-14,151,000
    EBIT$27.57M$-5,903,000$-6,414,000$-5,692,000$-7,503,000$-16,638,000$-7,505,000$-12,601,000$-12,418,000$-9,597,000$-10,343,000$-14,351,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ATNM

    News

    Actinium Pharmaceuticals names Matt David as CFO By Investing.com

    Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) has appointed Matt David, M.D., as its new Chief Financial Officer. Dr. David will manage the company's financial operations, including accounting, capital markets...

    Investing.com Nigeria•10/15/26•Bullish

    Actinium Pharmaceuticals Appoints Matt David CFO to Support Radiotherapy Pipeline Development

    Actinium Pharmaceuticals (NYSE American: ATNM) has appointed Matt David, M.D., as its new Chief Financial Officer. David brings over 20 years of biopharmaceutical leadership and capital markets experience...

    citybiz•10/15/26•Neutral

    Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

    Actinium Pharmaceuticals announced an upcoming oral presentation at the EANM 2026 conference, detailing early results from their first-in-human Phase 1 study of ATNM-400. This non-PSMA targeting radiotherapy aims...

    PR Newswire•10/15/26•Bullish

    Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

    Actinium Pharmaceuticals, a pioneer in targeted radiotherapies, has appointed Matt David, M.D., as its new Chief Financial Officer. Dr. David brings over two decades of experience in biopharmaceutical leadership...

    PR Newswire•10/15/26•Bullish

    Actinium Pharmaceuticals names Matt David as CFO

    Actinium Pharmaceuticals (NYSE American: ATNM) has appointed Matt David, M.D., as its new Chief Financial Officer, effective October 15, 2026. Dr. David will oversee finance, accounting, capital markets...

    StreetInsider•10/15/26•Bullish

    ATNM Valuation and Fair Value

    P/E
    2.9x
    Forward P/E
    8.5x
    EV/EBITDA
    -0.4x
    PEG
    0.0x
    P/B
    1.1x
    See GNG's fair value

    ATNM Profitability: Margins, ROIC and FCF

    Operating margin
    78.8%
    Net margin
    32.2%
    ROE
    45.9%
    FCF margin
    -66.2%

    ATNM Competitors

    CompanyTicker
    Milestone ScientificMLSS
    Barinthus Biotherapeutics plcBRNS
    CEL-SCI CorpCVM
    DocGo IncDCGO
    Rockwell Medical IncRMTI
    NextCure IncNXTC
    Briacell Therapeutics CorpBCTX
    Nortech Systems IncorporatedNSYS

    Sector: Healthcare

    ATNM Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    1
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ATNM Bull Case vs Bear Case

    Bull case

    • ATNM has a 32.2% net profit margin.

    Bear case

    • ATNM's quarterly revenue changed -100.0% year over year.

    ATNM Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    76.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.26
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About ATNM

    Does ATNM pay dividends?

    Actinium Pharmaceuticals Inc (ATNM) does not currently pay a regular dividend.

    What is ATNM's P/E ratio?

    Actinium Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 2.92.

    What is ATNM's market cap?

    Actinium Pharmaceuticals Inc (ATNM) has a market capitalization of $30.64M with a current stock price of $1.05.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In